Building AI-Ready Clinical Trials Through Unified, Compliant Systems

Source: DIA Global Forum

Author:
Harsha K. Rajasimha
Jeeva Clinical Trials Inc.

Isaac R. Rodriguez-Chavez
4Biosolutions Consulting

The Convergence We Can No Longer Ignore

Clinical trials are growing more complex even as expectations for efficiency, inclusiveness, and transparency continue to rise. Sponsors are navigating modern clinical trials with decentralized elements, Artificial Intelligence (AI)-enabled analytics, electronic source data, digital endpoints, and global regulatory expectations, often across fragmented legacy systems that were never designed to interoperate.

Meanwhile, regulators are signaling a future where data integrity, traceability, and algorithmic transparency are non-negotiable. The question is not whether clinical research will become technology-native (i.e., built from the ground up with digital innovation). It is whether we will build it responsibly aligned with regulatory science, patient protection, and operational excellence. The emerging architecture of modern clinical trials, the US Food and Drug Administration’s (FDA) Digital Health Technologies (DHT) guidance, its 2023 risk-based monitoring recommendations to monitor clinical investigations and to manage quality risk, the modern quality-by-design and risk-based quality management principles in ICH E6(R3) and ICH Q9(R1), and the agency’s expanding real-world evidence framework all signal a unified regulatory direction: a shift toward risk-proportionate, data-driven, technology-enabled oversight of clinical trials. The FDA’s 2023 DHT guidance explicitly states that remote data collection tools must demonstrate fitness for purpose, robust validation, and secure data transmission to be acceptable in regulated trials.

Over the past five years, three structural shifts have reshaped clinical research:

1. Modern Clinical Trial Models With Decentralized Elements
   Remote visits, wearable sensors, telemedicine, and electronic informed consent (eConsent) have expanded access. The pandemic accelerated these models, but sustainability depends on regulatory compliance that includes 21 CFR Part 11, the European Union General Data Protection Regulation (GDPR), and evolving global data protection requirements. Large-scale virtual studies such as the Apple Heart Study, which enrolled more than 400,000 participants remotely and demonstrated that smartwatch-based irregular pulse notifications can safely identify atrial fibrillation, show that decentralized evidence generation is feasible at population scale.
2. AI-Enabled Decision Support
   Artificial intelligence is now embedded in protocol design, patient matching, risk-based monitoring, and data anomaly detection. The FDA’s discussion paper on AI/ML in Drug Development highlights both promise and caution. Artificial intelligence-supported central monitoring approaches have already demonstrated improved detection of atypical data patterns compared with traditional monitoring alone, as shown in multisponsor analyses published by TransCelerate BioPharma.
3. Interoperability with Healthcare Systems
   Integration with electronic health records (EHRs), claims databases, and registries is increasingly expected. However, interoperability standards such as Health Level Seven Fast Healthcare Interoperability Resources (HL7 FHIR) and the Clinical Data Interchange Standards Consortium (CDISC) models are unevenly adopted across sites and countries. The ADAPTABLE trial, which randomized 15,076 patients using the National Patient-Centered Clinical Research Network’s (PCORnet) EHR-enabled infrastructure, demonstrates that interoperable data networks support large, pragmatic trials with reduced administrative burdens and efficient, direct-to-patient recruitment. While effective in reducing site burden, the study’s virtual, direct-to-patient design resulted in challenges regarding substantial dose switching and significant missingness of patient-reported data.

Despite these advances, most clinical trials still operate on siloed systems: separate platforms for clinical trial management systems (CTMS), electronic data capture (EDC), electronic clinical outcome assessments (eCOA), eConsent, safety reporting, and monitoring. This fragmentation introduces:

• Redundant data entry
• Inconsistent audit trails
• Delayed signal detection
• Increased inspection risk
• Cybersecurity vulnerabilities.

Regulatory frameworks emphasize accountability and traceability. Yet our technical infrastructure often undermines those very principles.

The Regulatory Crossroads: Compliance in an AI-Native World

Regulatory science is evolving to accommodate innovation but not at the expense of data integrity or patient safety.

Several regulatory themes are converging:

• Transparency of Algorithms
  Agencies increasingly expect explainability in AI-driven outputs. The EMA’s 2024 Reflection Paper on AI emphasizes that opaque “black‑box” models are unlikely to be acceptable for high‑stakes decisions without clear explainability and human oversight.
• Data Provenance and Auditability
  ICH E6(R3) reinforces sponsor responsibility for oversight of computerized systems. Under ICH E6(R3), sponsors remain accountable for vendor‑managed systems, including validation, change control, and maintenance of complete, contemporaneous audit trails.
• Cybersecurity as Patient Protection
  The FDA’s growing emphasis on cybersecurity in medical devices has implications for digital trial systems. Cybersecurity frameworks such as ISO/IEC 27001:2022 and ISO/IEC 27701:2025 are increasingly referenced by regulators as benchmarks for protecting clinical trial data environments.
• Use of Real-World Data and Digital Endpoints
  While agencies support innovation, they require robust validation and pre-specification. The EMA’s 2023 qualification of the wearable‑derived stride velocity 95th centile (SV95C) as a primary endpoint in ambulant Duchenne muscular dystrophy trials demonstrates that regulators will accept digital endpoints when supported by rigorous analytical and clinical validation.

This creates a regulatory gap: Innovation is accelerating faster than harmonized guidance. Companies must design compliance into technology architecture, not retrofit it later.

Building Compliance by Design: A Unified, AI-Ready Infrastructure

Experience across large, technology-enabled research initiatives has shown that compliance is not a documentation exercise; it is an architectural discipline. Publicly available platforms such as FDA’s MyStudies illustrate how interoperable, audit-ready infrastructures can support decentralized and AI-enabled research while maintaining regulatory-grade data integrity. To responsibly enable AI and decentralized research, modern clinical trial platforms purpose-built to address the friction and fragmentation of legacy systems should incorporate:

• Role-based access controls and dynamic delegation logs
• End-to-end audit trails across all modules
• Validated AI model governance frameworks
• Integrated risk-based monitoring dashboards
• Standardized application programming interfaces (APIs) aligned with HL7 FHIR and CDISC
• Built-in electronic source documentation controls.

A unified infrastructure reduces reconciliation errors and improves inspection readiness. Risk‑based quality management principles from ICH E8(R1) and E6(R3) can be operationalized through integrated dashboards that link central monitoring signals, site performance metrics, and data-quality indicators.

When AI assistants perform data cleaning or protocol optimization, their actions should be logged, validated, and reproducible. When wearable data streams into a trial database, provenance should be preserved. When sites enter data remotely, system validation should withstand regulatory scrutiny.

This is not theoretical. It is the new operational baseline. For example, recent work underscores this shift. A 2023 study shows that decentralized elements added to trials require interoperable, audit-ready digital infrastructures to maintain data integrity and reduce quality risks, reinforcing the need for unified platforms with built-in traceability and validation.

Likewise, a 2026 HITLAB white paper demonstrates how modular, technology-enabled clinical trial platforms can streamline remote data capture, strengthen inspection readiness, and embed quality-by-design features such as centralized monitoring and structured eSource controls.

Together, these examples show that compliance by design is already being implemented through architectures that integrate interoperability, validation, and risk-based oversight into the core of modern clinical trial systems.

Implications for Sponsors, Sites, and Regulators

The shift to AI-native, interoperable platforms has wide-ranging implications.

For Sponsors:

• Greater efficiency through automation
• Earlier safety signal detection
• Reduced monitoring travel burden
• Increased responsibility for vendor oversight and AI validation

Sponsors should integrate AI and digital technology oversight into their quality management systems, including formal vendor qualification and ongoing performance monitoring.

For Sites:

• Streamlined workflows
• Reduced duplicative data entry
• Enhanced patient engagement tools
• New training requirements on digital systems and AI outputs

Digital literacy and understanding of AI‑generated alerts are becoming core competencies for site personnel.

For Regulators:

• Improved access to structured, standardized data
• More transparent audit trails
• Need for harmonized guidance on AI validation standards

Regulators are increasingly using pilot programs and regulatory sandboxes to evaluate novel digital endpoints and AI tools in controlled environments.

AI Governance: The Next Frontier in Clinical Research Compliance

Artificial intelligence introduces both operational leverage and regulatory complexity. The FDA has emphasized the importance of lifecycle management for AI/ML systems. In clinical trials, this translates into:

• Documented training data sets
• Version control of algorithms
• Ongoing performance monitoring
• Pre-specified thresholds for decision-making
• Clear delineation between automated recommendations and human oversight.

AI governance frameworks should include bias-assessment methods, revalidation triggers, and procedures for decommissioning models that no longer meet performance or fairness criteria.

Equally important, AI in clinical research must function as an augmentation tool, not a replacement for clinical judgment, with every algorithmic output remaining explainable, reviewable, and traceable to support regulatory expectations for human oversight.

The future of AI in trials will be shaped less by technical sophistication and more by trust, which is earned through transparent validation, lifecycle monitoring, and alignment with global regulatory science principles.

Regulators increasingly expect AI systems used in clinical research to demonstrate a plausible mechanism, that is, a scientifically coherent explanation for how model inputs lead to outputs, so that human reviewers can assess validity, limitations, and potential risks.

The Role of Standard Healthcare Systems

Modern trials cannot remain isolated from routine healthcare systems. Integration with EHRs and registries enables:

• Faster feasibility assessments
• Improved representation in recruitment
• Reduced site burden
• Real-time safety surveillance.

EHR‑enabled recruitment strategies have been shown to increase enrollment of underrepresented populations, as demonstrated in PCORnet‑supported cardiovascular and diabetes studies.

However, interoperability introduces new challenges:

• Data normalization
• Privacy compliance under the Health Insurance Portability and Accountability Act (HIPAA) and GDPR
• Consent management across jurisdictions
• Cross-border data transfer restrictions

Digital endpoints such as SV95C have shown greater sensitivity to short‑term functional decline than traditional measures like the six‑minute walk test, underscoring the value of continuous real‑world data streams.

A technology-enabled trial should reconcile clinical care data with research-grade data standards. For example, clinical care data in electronic medical records (EMRs) are usually re-entered in EDC systems used in clinical trials. This double data entry problem is well known and causes significant burden on site coordinators. This requires a unified digital architecture rather than a series of ad hoc integrations.

Strategic Alignment: A Path Forward

The modernization of clinical trials is no longer optional. It is an ethical and scientific necessity. But progress requires coordinated action.

Researchers and Sponsors (Next 12–24 Months):

• Invest in unified, interoperable platforms rather than layering additional point solutions.
• Implement AI governance frameworks with documented validation plans.
• Align digital endpoint strategies early with regulatory consultation.

Technology Providers:

• Design compliance into system architecture.
• Prioritize explainability in AI modules.
• Enable seamless integration with healthcare standards such as HL7 FHIR.

Regulators and Policymakers:

• Continue advancing harmonized guidance on AI/ML lifecycle management.
• Encourage pilot programs for digital endpoint validation.
• Foster global dialogue on cross-border data governance.

Clinical Sites:

• Strengthen digital literacy and cybersecurity awareness.
• Participate in validation studies for digital tools.
• Advocate for simplified, integrated workflows.

The expected outcome of these coordinated efforts is not simply faster trials. It is safer, more inclusive, more reliable research.

The Future We Must Build

Clinical research is entering a defining decade. Biologics, cell and gene therapies, precision medicine, and digital health technologies are expanding rapidly. The infrastructure supporting them must evolve accordingly.

We have an opportunity to move from fragmented, reactive compliance toward unified, AI-ready systems built on regulatory alignment and patient trust.

If stakeholders align on architecture, governance, and interoperability, the next decade could deliver trials that are faster, fairer, and more reliable than any in history.

As leaders in this field, we must ensure that innovation serves integrity. The transformation of clinical trials is not about replacing humans with algorithms. It is about equipping researchers, sites, and regulators with technology that strengthens accountability, transparency, and efficiency.

If we act deliberately, architecting compliance into every layer of digital infrastructure, we can accelerate therapies while preserving the scientific rigor and ethical standards that define our profession.

The tools are here. The regulations are evolving. The responsibility is ours.